ArticleRegulatory toxicology and pharmacology : RTP2026
New approach methodologies in food safety: A survey and commentary on industry adoption, barriers, and the path to regulatory adoption.
Article in Regulatory toxicology and pharmacology : RTP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
New approach methodologies (NAMs) are increasingly recognized as essential tools for modernizing regulatory science, yet their adoption in food safety risk assessment is not well characterized. To address this gap, we conducted a landscape analysis of NAMs use across the food industry. An anonymous survey was conducted between February and April 2026 with responses from seventeen international companies. Fourteen respondents reported using NAMs in the previous five years. Conventional cell-based assays, in silico toxicodynamic models, threshold of toxicological concern frameworks, and physiologically based pharmacokinetic (PBPK) modeling represented the most adopted approaches. More advanced platforms such as organ-on-chip systems were not routinely used. NAMs were predominantly applied to internal screening and prioritization, with ten companies reporting either experience with or interest in regulatory submissions incorporating NAMs-derived data. Novel food ingredients was the primary application area. Despite the interest in NAMs, significant barriers persist to their use in regulatory submissions, including challenges in data interpretation, limited availability of formally validated or qualified methods, high cost, and lack of specialized expertise to generate and interpret data. Regulatory acceptance emerged as the dominant factor influencing both internal adoption and submission decisions. Respondents indicated strong willingness to engage regulators through voluntary data-sharing mechanisms under appropriate "safe-space" conditions. These findings indicate that NAMs use in the food sector is established, but remains constrained and that progress toward broader regulatory integration will depend on fit-for-purpose guidance, clearly defined contexts of use, and improved frameworks for evidence integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.